Targeted gene editing in cancer cells using a specialized delivery system
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells
['FUNDING_R21'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-10993673
This study is exploring a new way to use gene editing to target cancer cells more precisely, which could lead to better treatments with fewer side effects for patients like you.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-10993673 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to gene editing in tumor cells by utilizing a specialized delivery system that combines a modified adeno-associated virus with CRISPR technology. The goal is to create targeted therapies that specifically edit cancer cells while minimizing effects on healthy cells. By using a unique phage capsid to direct the gene editing tools precisely where they are needed, this method aims to enhance the effectiveness of cancer treatments. Patients may benefit from more effective therapies that reduce side effects associated with traditional treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that express unique cellular markers.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not express identifiable markers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments that specifically target tumor cells.
How similar studies have performed: Previous research has shown promise in using targeted gene editing approaches in cancer therapy, indicating potential for success with this novel method.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PASQUALINI, RENATA — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: PASQUALINI, RENATA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.